Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrase inhibitor MK-0518: Merck opens expanded-access program.

John S James

    AIDS Treatment News
    |November 14, 2006
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Activism and online fundraising: overview.

    AIDS treatment news·2007
    Same author

    "Fundathon": toward massively multiplayer online fundraising games.

    AIDS treatment news·2007
    Same authorSame journal

    Selling digital art in bulk through prepaid URLs.

    AIDS treatment news·2007
    Same authorSame journal

    Financial accounts that can reproduce, inherit, and evolve.

    AIDS treatment news·2007
    Same authorSame journal

    AIDS search engine wanted: what to do now?

    AIDS treatment news·2007
    Same author

    Prisoner death rate very high immediately after release.

    AIDS treatment news·2007
    Same journal

    New kind of antiretroviral, KP-1461; clinical trial recruiting. Interview with Stephen Becker, M.D.

    AIDS treatment news·2008
    Same journal

    Flu shot reminder.

    AIDS treatment news·2008
    Same journal

    Is cure possible for HIV?

    AIDS treatment news·2007
    See all related articles

    New antiretroviral therapies offer hope for patients with multidrug-resistant HIV. These novel drugs must still be used in combination with other active treatments for efficacy.

    Area of Science:

    • Virology
    • Infectious Diseases
    • Drug Development

    Background:

    • Multidrug resistance in Human Immunodeficiency Virus (HIV) presents a significant clinical challenge.
    • Existing oral antiretroviral drug classes have limitations in treating resistant strains.

    Discussion:

    • A new class of antiretroviral medication is emerging for patients with resistance to multiple oral drugs.
    • This novel agent requires combination therapy with other active antiretroviral drugs.

    Key Insights:

    • Patients with resistance to all three oral antiretroviral classes are candidates for this new therapeutic option.
    • The development of novel antiretrovirals is crucial for managing complex HIV infections.

    Outlook:

    Related Experiment Videos

  • Further research is needed to fully understand the long-term efficacy and safety of this new antiretroviral.
  • Continued innovation in antiretroviral drug development is essential to combat evolving HIV resistance patterns.